National survey of hemapheresis practice in Turkey (1998)

• Published in: Transfusion science Vol. 22; no. 3; pp. 195 - 201
• Main Authors: Ilhan, Osman, Üskent, Necdet, Arslan, Önder, Arat, Mutlu, Özkalemkaş, Fahir, Öztürk, Gülyüz, Kalayoǧlu, Sevgi B., Özet, Ahmet, Tombuloǧlu, Murat, Arpacı, Fikret, Ovalı, Ercüment, Anak, Sema
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2000
• Subjects: Adolescent; Adult; Blood Component Removal - adverse effects; Blood Component Removal - standards; Blood Component Removal - utilization; Child; Data Collection; Female; Health technology assessment; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation - adverse effects; Hematopoietic Stem Cell Transplantation - standards; Hematopoietic Stem Cell Transplantation - utilization; Humans; Male; Middle Aged; Plasma Exchange - utilization; Plateletpheresis; Registries; Tissue Donors; Transplantation, Autologous; Transplantation, Homologous; Turkey; Turkey
• ISSN: 0955-3886; 1879-3126
• DOI: 10.1016/S0955-3886(00)00057-6

The Turkish Apheresis Group has maintained a national registry for apheresis activities since 1997. The hemapheresis practice of Turkey in 1998 is summarized in brief detail in this article. A total of 30,136 apheresis procedures were performed at 31 different apheresis centers. At 10 centers, 145 peripheral blood stem cell (PBSC) apheresis were performed on 82 patients in allogeneic setting and at 17 centers, 981 PBSC apheresis were performed on 271 patients in autologous setting. Frequently observed adverse effects during PBSC apheresis were mild tremor and chills, paresthesia and nausea in 15% of the patients and donors. Vascular access complications, particularly observed in autologous setting due to central venous catheters were encountered in 10% of the procedures. Eight hundred and sixty-nine therapeutic plasma exchange procedures were performed at 21 centers on 172 patients, most commonly for neurological disorders and thrombotic thrombocytopenic purpura (TTP)/hemolyic uremic syndrome (HUS). Therapeutic cytapheresis procedures like leukapheresis, plateletapheresis and erythrocyte apheresis were performed especially for cytoreduction in myeloproliferative disorders. A total of 204 cytapheresis procedures (66% leukapheresis, 33% plateletapheresis and 1% erythrocytapheresis) were performed on 134 patients in 15 centers. Donor plateletapheresis was the most used apheresis procedure, reaching a total of 28.016 in 1998. Many university hospitals and a few state hospitals are performing above-mentioned apheresis procedures with great success and acceptable side effects. According to these data we are planning prospective trials and will establish National Standards of Practice.